Go Pro
NASDAQ:NTHI

Neonc Technologies Q1 2025 Earnings Report

Neonc Technologies logo
$3.43 -0.20 (-5.51%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$3.46 +0.03 (+0.87%)
As of 07/24/2026 05:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Neonc Technologies EPS Results

Actual EPS
-$2.10
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Neonc Technologies Revenue Results

Actual Revenue
$0.04 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Neonc Technologies Announcement Details

Quarter
Q1 2025
Time
After Market Closes
Conference Call Date
Friday, May 9, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

Neonc Technologies' Q2 2026 earnings is estimated for Friday, August 14, 2026, based on past reporting schedules, with a conference call scheduled on Monday, August 17, 2026 at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Neonc Technologies Earnings Headlines

NeOnc Technologies Holdings Inc.
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in 50 years - and it has nothing to do with a single stock. According to multiple Wall Street banks, a coming crisis could keep your portfolio in the red for 10 years or longer. Keith Kaplan, CEO of TradeSmith, is sharing what you can do to protect your wealth before it hits.tc pixel
Wall Street is Watching These Biotechs
See More Neonc Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Neonc Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Neonc Technologies and other key companies, straight to your email.

About Neonc Technologies

Neonc Technologies (NASDAQ:NTHI) develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.

View Neonc Technologies Profile